Zongertinib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Zongertinib
- Molecular weight
- 535.61
- Structure (SMILES)
- C=CC(=O)NC1CCN(c2ncc3ncnc(Nc4ccc(Oc5ccc6c(c5)ncn6C)c(C)c4)c3n2)CC1
- bi 1810631
- BI 1810631
- BI-1810631
- bi1810631
- BI1810631
- hernexeos
- HERNEXEOS
- zongertinib
- Zongertinib
- Zongertinib (BI 1810631)
- zongertinib (C-14)
- zongertinib [INN]
- ZONGERTINIB [USAN]
- Zongertinib [WHO-DD]
- zongertinib inn
- zongertinib usan
- zongertinib who dd
- ATC classification codes
- L01EH04
Sources for recorded values
- CAS registry numbers
- 2728667-27-2
- ChEMBL ID
- CHEMBL5314498
- InChIKey
- YSGNGFPNTLERCR-UHFFFAOYSA-N
- PubChem compound IDs
- 160283094
- RxNorm IDs (RxCUI)
- 2721604
- FDA ingredient codes (UNII)
- DRH7R67UVL
- Patents
- 2
- Designations
- 6
- Earliest recorded loss of exclusivity
- 21 Jul 2041
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Pharmacology name
- zongertinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- epidermal growth factor receptor
- Gene symbol
- EGFR
- Protein identifier
- P00533
- Median affinity
- 6.24
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- erb-b2 receptor tyrosine kinase 2
- Gene symbol
- ERBB2
- Protein identifier
- P04626
- Median affinity
- 7.89
- Affinity units
- pIC50
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002715
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004669
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005028
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005036
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0056806
- Highest recorded phase
- 2
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 2
- Polar surface area
- 122.98
- Calculated partition coefficient (ALogP)
- 4.42
- Calculated partition coefficient (XLogP)
- 4.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 40
- Molecular formula
- C29H29N9O2
- Monoisotopic mass
- 535.24442120
- Natural product
- No
- 0597-9257
- Recorded assays
- 51
- Active assays
- 7
Active assay types
- Confirmatory
Related records
Trials (18)
- A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.
- A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood
- A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the Blood
- A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the Body
- A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without Food
- A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the Blood
- A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
- A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
- A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers
- A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without Food
- A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems
- Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
In development for (2)
- Liver disorder Phase 1
- Neoplasm Phase 1